Research Compound GHRH Analogue · No DAC Clinic Preference — Controllable

Mod-GRF 1-29

CJC-1295 without DAC · Modified GRF (1-29) · Tetrasubstituted GHRH 1-29

"The controllable version. CJC-1295 without the Drug Affinity Complex — a 29-amino acid GHRH analogue that peaks in 30 minutes and clears in 3 hours. Preferred by physicians who want predictable GH pulses rather than the sustained week-long elevation of CJC-1295 with DAC."

Structure
29 AA · GHRH analogue · 4 substitutions
Half-life
~30 min (vs 6–8 days for CJC-DAC)
FDA Status
Not approved · research compound
Key advantage
Controllable · stops quickly · clinic preferred
WADA
Prohibited
Origin & Background

The controllable GHRH analogue

Mod-GRF 1-29 is a modified version of sermorelin (GHRH 1-29) with four amino acid substitutions designed to improve stability against enzymatic degradation without adding the albumin-binding DAC modification that gives CJC-1295 its 6–8 day half-life. The substitutions replace four amino acids at positions 2, 8, 15, and 27 with amino acids resistant to DPP-4 and other serum peptidases.

The name confusion around this compound is notorious — it is frequently sold as "CJC-1295" when it is in fact CJC-1295 without DAC. True CJC-1295 has the Drug Affinity Complex modification that extends its half-life to 6–8 days. Mod-GRF 1-29 lacks this modification, giving it a half-life of approximately 30 minutes — comparable to sermorelin but with greater stability than unmodified GHRH 1-29.

Clinicians increasingly favour Mod-GRF 1-29 over CJC-1295 (with DAC) for several reasons: the shorter half-life is more controllable — if a patient has side effects, the peptide clears within hours rather than persisting for a week. It also allows more physiological pulsatile GH patterns when dosed 2–3 times daily alongside a GHRP, rather than the sustained continuous elevation produced by CJC-1295 DAC.

The naming confusion: Many suppliers sell Mod-GRF 1-29 labelled as "CJC-1295 without DAC" — which is technically accurate but creates confusion with CJC-1295 (with DAC), which has a fundamentally different half-life and dosing protocol. When purchasing, confirm which version you have: if it requires daily or 3x daily dosing, it is Mod-GRF 1-29. If it is weekly, it is CJC-1295 with DAC.

Science & Mechanism

Four substitutions — same receptor

Mechanism of Action

1
GHRHR binding: Mod-GRF 1-29 binds the same GHRH receptor as sermorelin and CJC-1295, stimulating pulsatile GH release from pituitary somatotrophs. The mechanism is identical — only the pharmacokinetics differ.
2
Four amino acid substitutions: Position 2 (Ala→D-Ala), position 8 (Asn→Gln), position 15 (Gly→Ala), position 27 (Met→Nle). These substitutions confer DPP-4 resistance and improve overall peptide stability without albumin binding.
3
30-minute half-life: Without the DAC albumin-binding modification, Mod-GRF 1-29 peaks at 30 minutes and is largely cleared within 2–3 hours. This produces a clean, defined GH pulse rather than the sustained elevation of CJC-1295 DAC.
4
Physiological pulsatile pattern: When dosed 2–3 times daily with a GHRP, Mod-GRF 1-29 mimics the natural GHRH + ghrelin pulsatile GH release pattern more closely than once-weekly CJC-1295 DAC. Some practitioners consider this more physiological.
5
Synergy with GHRPs: Same powerful synergy as CJC-1295 — combined with ipamorelin, GHRP-2, or GHRP-6, produces 3–5x more GH than either compound alone. The short half-life means the synergy window is the 30–60 minutes around injection rather than a sustained multi-day effect.
Community Voices

What people report

Anecdotal ReportNot medical evidence · Individual experience

"My clinic switched me from CJC-1295 DAC to Mod-GRF/ipamorelin. The doctor preferred it because she could adjust or stop quickly if needed. I do three daily injections which is more hassle but my IGF-1 is in range and the sleep effect is cleaner — I don't get the water retention I had on DAC."

Female, 49, functional medicine patient. The physician preference for controllability is the most commonly cited reason for clinical switching from CJC-DAC to Mod-GRF. The 3x daily injection burden is the main practical downside.

Anecdotal ReportNot medical evidence · Individual experience

"I had significant water retention on CJC-1295 DAC that wouldn't resolve. Switched to Mod-GRF and it cleared within two weeks. The GH effect feels more pulse-like — I notice the deep sleep more acutely around the bedtime injection rather than the constant background elevation of DAC."

Male, 44. Water retention differences between the two CJC variants are consistently reported — the sustained GH elevation from CJC-DAC produces more persistent IGF-1-mediated sodium retention than the pulsatile pattern from Mod-GRF.

Benefits & Evidence

What the data shows

🎛️
Controllable GH pulse — physician preferred
The 30-minute half-life means GH elevation is predictable and time-limited. If side effects appear, stopping the compound resolves them within hours rather than the days-to-weeks required for CJC-1295 DAC to clear. This controllability is the primary clinical advantage.
● Moderate — pharmacokinetic rationale
💉
GH/IGF-1 elevation and body composition
Same downstream effects as sermorelin and CJC-1295 — GH elevation drives IGF-1, which drives lean mass gain, fat loss, improved recovery and sleep. The body composition evidence is extrapolated from the class rather than specific to this compound.
● Moderate — class extrapolation from GHRH analogue data
🔁
Physiological pulsatility (potential advantage)
Multiple daily injections with Mod-GRF produce GH release in defined pulses — more closely mimicking natural GH secretion patterns than the sustained elevation from weekly CJC-DAC. Whether this pulsatility advantage translates into better clinical outcomes has not been formally studied.
● Limited — theoretical advantage, not tested head-to-head
💤
Sleep and recovery (consistent reports)
Bedtime Mod-GRF + ipamorelin injection produces an acute GH pulse during early slow-wave sleep — the most common protocol reported to improve sleep quality and recovery. Effect is well-characterised in community reports.
● Moderate — consistent across community reports
Safety First

Risks & considerations

🛡️
Safer class profile than CJC-1295 with DAC. The short half-life means side effects can be managed by stopping the compound — they resolve quickly rather than persisting for days. Same class risks as all GHRH analogues, but with better reversibility.
Mild
Injection site reactions — standard SubQ injection reactions. Less frequent per-dose than CJC-DAC since the injection burden is higher (3x daily vs weekly).
Mild
Flushing and headache — transient, typically first 2 weeks. More acute per-injection than CJC-DAC due to sharper GH pulses.
Moderate
Water retention and joint discomfort — less than CJC-1295 DAC for most users due to lower sustained IGF-1 elevation, but still present at higher doses.
Moderate
IGF-1 monitoring required — same as all GH secretagogues. Monitor every 3 months and keep within age-appropriate range.
Serious
Contraindicated in active malignancy — same class contraindication as all GH axis stimulants.

⚠ Key Warnings

Confirm what you have — "CJC-1295 without DAC" and Mod-GRF 1-29 are the same compound, but some suppliers mislabel CJC-1295 with DAC as "without DAC." If dosing is once weekly it is the DAC version regardless of label.
3x daily injection protocol requires compliance and sterile technique at every injection. More injection events means more infection risk if technique is not meticulous.
WADA: prohibited at all times for all competitive athletes.
Synergy Stack

Nutrients, Supplements & Exercise

Mod-GRF 1-29 is always used in combination with a GHRP — this is where its effect is maximised. The synergy stack is therefore the GHRP combination plus the supporting nutrients for the GH/IGF-1 environment.

💊 Nutrients & Supplements
Ipamorelin (co-injection)
100–200mcg with each Mod-GRF dose
Strong evidence
The defining synergy. Mod-GRF 1-29 + ipamorelin at the same injection produces 3–5x the GH of either alone. This is the most popular clinic combination — clean, controllable, with no cortisol or hunger side effects from either compound. Inject simultaneously.
Fasted injection
No carbs 2h before each dose
Strong evidence
Insulin suppresses GH release. All three daily injections should be fasted — morning (before breakfast), post-workout (before eating), and bedtime (2+ hours after dinner). This maximises the GH pulse from each injection.
Zinc
15–25mg/day
Moderate evidence
Required for pituitary GHRH receptor function and IGF-1 signalling. Deficiency blunts the pituitary response to Mod-GRF stimulation.
Magnesium glycinate
300mg before bed
Moderate evidence
Deepens slow-wave sleep — amplifying the GH pulse from the bedtime Mod-GRF/ipamorelin injection. The bedtime dose is the most important for body composition and recovery outcomes.
🏃 Exercise & Lifestyle
Three-injection protocol timing
Morning (fasted): primes GH axis for the day. Post-workout (fasted): amplifies exercise-induced GH pulse. Bedtime (fasted, 2h+ after food): captures the largest natural GH pulse of the day during slow-wave sleep. All three work — most practitioners prioritise bedtime if compliance with 3x daily is difficult.
Resistance training — evening
Train in the evening then inject Mod-GRF/ipamorelin before bed — layering the exercise-induced GH pulse with the peptide-induced pulse and the sleep GH pulse for maximum nocturnal GH output.
Consistent sleep timing
The bedtime injection is optimised by consistent sleep timing — going to bed at the same time every night maximises slow-wave sleep onset and therefore the GH pulse timing.
⏱ Timing & Protocol Notes
Most common: 100mcg Mod-GRF + 100–200mcg ipamorelin, injected together 2–3x daily. All injections fasted. Cycle 12–16 weeks on, 4–6 weeks off. Monitor IGF-1, fasting glucose every 3 months. If compliance with 3x daily is difficult, bedtime-only dosing is a reasonable simplified protocol.

Disclaimer: Educational information only. Research compound requiring physician oversight. IGF-1 monitoring is essential.

Honest Assessment

Editor's summary

Mod-GRF 1-29 is neither better nor worse than CJC-1295 with DAC — it is different in a way that matters clinically. The shorter half-life gives physicians and users the ability to stop and see effects resolve quickly, rather than being committed to a week-long GH elevation after each injection. This controllability is genuinely valuable in a clinical context.

The practical downside is the injection burden — three daily injections vs once weekly for CJC-DAC is a significant compliance difference. For self-injecting community users, this is often the deciding factor. For medically supervised protocols where physician confidence in dose control matters, Mod-GRF is increasingly the preferred option.

Combined with ipamorelin (the standard clinic protocol), Mod-GRF 1-29 provides the same GH synergy as CJC-1295/ipamorelin with more predictable and controllable pharmacokinetics. The body composition and sleep effects are consistent with the rest of the GHRH analogue class.

Verdict
"The physician's choice for GHRH — controllable, predictable, and reversible. Same GH synergy with ipamorelin as CJC-1295 DAC, but with a 30-minute half-life that allows dose adjustments and side effect management. The compliance cost of 3x daily injections is the trade-off."